Other OVs, like engineered HSV-1 and influenza A viruses, have shown enhanced antitumor responses when combined with ipilimumab, primarily by increasing immune cell infiltration (CD4+, CD8+ T cells) and reducing immunosuppressive Tregs in the tumor microenvironment. This evidence concerns the gene CD4 and neoplasm.